The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics

Osteoarthritis and Cartilage

Volumn 22, Issue 5, 2014, Pages 609-621

  Tonge, D P ^b   Pearson, M J ^a   Jones, S W ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b STAFFORDSHIRE UNIVERSITY   (United Kingdom)

Author keywords

OA; Osteoarthritis; Patient stratification; Personalised medicine

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; LICOFELONE; MATRIX METALLOPROTEINASE INHIBITOR; OSTEOGENIC PROTEIN 1; SELECTIVE ANDROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADIPOSE TISSUE; AGING; BONE REMODELING; CARTILAGE DEGENERATION; CARTILAGE MATRIX; DRUG TARGETING; EVIDENCE BASED PRACTICE; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; MYOPATHY; NONHUMAN; OSTEOARTHRITIS; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES; SKELETAL MUSCLE;

ADIPOSE TISSUE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE REMODELING; HUMANS; MOLECULAR TARGETED THERAPY; MUSCLE, SKELETAL; OSTEOARTHRITIS; PRECISION MEDICINE;

EID: 84899974872     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.03.004     Document Type: Review

References (143)

1. Peat G., Thomas E., Handy J., Wood L., Dziedzic K., Myers H., et al. The Knee Clinical Assessment Study-CAS(K). A prospective study of knee pain and knee osteoarthritis in the general population. BMC Musculoskelet Disord 2004, 5:4.
2. Hunter D.J. Pharmacologic therapy for osteoarthritis-the era of disease modification. Nat Rev Rheumatol 2010, 7:13-22.
3. Coruzzi G., Venturi N., Spaggiari S. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. Acta Biomed 2007, 78:96-110.
4. Reginster J.Y., Badurski J., Bellamy N., Bensen W., Chapurlat R., Chevalier X., et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 2013, 72:179-186.
5. Singh J.A., Furst D.E., Bharat A., Curtis J.R., Kavanaugh A.F., Kremer J.M., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
6. Armour A.A., Watkins C.L. The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur Respir Rev 2010, 19:186-196.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
8. Mazurek S.G.N., Li J., Nabozny G.H., Reinhart G.A., Muthukumarana A.C., Harrison P.C., et al. Functional biomarkers of musculoskeletal syndrome (MSS) for early invivo screening of selective MMP-13 inhibitors. JPharmacol Toxicol Methods 2011, 64:89-96.
9. Lorenz H., Richter W. Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog Histochem Cytochem 2006, 40:135-163.
10. Tugwood J.D., Kelsall J., Coverley L.C., Westwood F.R., Haque K., Huby R.D.J. Fibrodysplasia induced in dog skin by a matrix metalloproteinase (MMP) Inhibitor-A mechanistic analysis. Toxicol Sci 2012, 127:236-245.
11. Baragi V.M., Becher G., Bendele A.M., Biesinger R., Bluhm H., Boer J., et al. Anew class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009, 60:2008-2018.
12. Amalinei C., Caruntu I.D., Giusca S.E., Balan R.A. Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol 2010, 51:215-228.
13. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. JCell Sci 2002, 115:3719-3727.
14. Zucker S., Cao J. Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time?. Cancer Biol Ther 2009, 8:2371-2373.
15. Krzeski P., Buckland-Wright C., Balint G., Cline G., Stoner K., Lyon R., et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007, 9:R109.
16. Renkiewicz R., Qiu L., Lesch C., Sun X., Devalaraja R., Cody T., et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003, 48:1742-1749.
17. Westwood R., Scott R.C., Somers R.L., Coulson M., Maciewicz R.A. Characterization of fibrodysplasia in the dog following inhibition of metalloproteinases. Toxicol Pathol 2009, 37:860-872.
18. Settle S., Vickery L., Nemirovskiy O., Vidmar T., Bendele A., Messing D., et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes. Arthritis Rheum 2010, 62:3006-3015.
19. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.-L., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
20. Stanton H., Rogerson F.M., East C.J., Golub S.B., Lawlor K.E., Meeker C.T., et al. ADAMTS5 is the major aggrecanase in mouse cartilage invivo and invitro. Nature 2005, 434:648-652.
21. Ellman M.B., An H.S., Muddasani P., Im H.-J. Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis. Gene 2008, 420:82-89.
22. Ellsworth J.L., Berry J., Bukowski T., Claus J., Feldhaus A., Holderman S., et al. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage 2002, 10:308-320.
23. Moore E.E., Bendele A.M., Thompson D.L., Littau A., Waggie K.S., Reardon B., et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005, 13:623-631.
24. Merrihew C., Kumar B., Heretis K., Rueger D.C., Kuettner K.E., Chubinskaya S. Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage. JOrthop Res 2003, 21:899-907.
25. Chubinskaya S., Kuettner K.E. Regulation of osteogenic proteins by chondrocytes. Int J Biochem Cell Biol 2003, 35:1323-1340.
26. Hunter D.J., Pike M.C., Jonas B.L., Kissin E., Krop J., McAlindon T. Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010, 11:232.
27. Badlani N., Oshima Y., Healey R., Coutts R., Amiel D. Use of bone morphogenic protein-7 as a treatment for osteoarthritis. Clin Orthop Relat Res 2009, 467:3221-3229.
28. Buckland-Wright C. Subchondral bone changes in hand and knee osteoarthritis detected by radiography. Osteoarthritis Cartilage 2004, 12(Suppl A):S10-S19.
29. Burr D.B., Gallant M.A. Bone remodelling in osteoarthritis. Nat Rev Rheumatol 2012, 8:665-673.
30. Radin E.L. Subchondral bone changes and cartilage damage. Equine Vet J 1999, 31:94-95.
31. Radin E.L., Paul I.L., Rose R.M. Role of mechanical factors in pathogenesis of primary osteoarthritis. Lancet 1972, 1:519-522.
32. Radin E.L., Rose R.M. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res 1986, 34-40.
33. Brandt K.D., Radin E.L., Dieppe P.A., van de Putte L. Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis 2006, 65:1261-1264.
34. Anderson-MacKenzie J.M., Quasnichka H.L., Starr R.L., Lewis E.J., Billingham M.E., Bailey A.J. Fundamental subchondral bone changes in spontaneous knee osteoarthritis. Int J Biochem Cell Biol 2005, 37:224-236.
35. Quasnichka H.L., Anderson-MacKenzie J.M., Bailey A.J. Subchondral bone and ligament changes precede cartilage degradation in guinea pig osteoarthritis. Biorheology 2006, 43:389-397.
36. Hayami T., Pickarski M., Zhuo Y., Wesolowski G.A., Rodan G.A., Duong L.T. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006, 38:234-243.
37. Neogi T. Clinical significance of bone changes in osteoarthritis. Ther Adv Musculoskelet Dis 2012, 4:259-267.
38. Williams T.G., Holmes A.P., Waterton J.C., Maciewicz R.A., Hutchinson C.E., Moots R.J., et al. Anatomically corresponded regional analysis of cartilage in asymptomatic and osteoarthritic knees by statistical shape modelling of the bone. IEEE Trans Med Imaging 2010, 29:1541-1559.
39. Davis A.J., Smith T.O., Hing C.B., Sofat N. Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. PLoS ONE 2013, 8:e72714.
40. Bingham C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507.
41. Nielsen R.H., Bay-Jensen A.C., Byrjalsen I., Karsdal M.A. Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthritis Cartilage 2011, 19:466-473.
42. Takahashi N., Sasaki T., Tsouderos Y., Suda T.S. 12911-2 inhibits osteoclastic bone resorption invitro. JBone Miner Res 2003, 18:1082-1087.
43. Canalis E., Hott M., Deloffre P., Tsouderos Y., Marie P.J. The divalent strontium salt S12911 enhances bone cell replication and bone formation invitro. Bone 1996, 18:517-523.
44. Pelletier J.P., Kapoor M., Fahmi H., Lajeunesse D., Blesius A., Maillet J., et al. Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1beta in the synovium. Ann Rheum Dis 2013, 72:250-257.
45. Hayami T., Zhuo Y., Wesolowski G.A., Pickarski M., Duong L.T. Inhibition of cathepsin K reduces cartilage degeneration in the anterior cruciate ligament transection rabbit and murine models of osteoarthritis. Bone 2012, 50:1250-1259.
46. Hou W.S., Li W., Keyszer G., Weber E., Levy R., Klein M.J., et al. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum 2002, 46:663-674.
47. Pennypacker B., Shea M., Liu Q., Masarachia P., Saftig P., Rodan S., et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009, 44:199-207.
48. Leung P., Pickarski M., Zhuo Y., Masarachia P.J., Duong L.T. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 2011, 49:623-635.
49. Stoch S.A., Zajic S., Stone J., Miller D.L., Van Dyck K., Gutierrez M.J., et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009, 86:175-182.
50. Duong L.T. Therapeutic inhibition of cathepsin K[mdash]reducing bone resorption while maintaining bone formation. BoneKEy Rep 2012, 1.
51. McDougall J.J., Schuelert N., Bowyer J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis. Osteoarthritis Cartilage 2010, 18:1355-1357.
52. Connor J.R., LePage C., Swift B.A., Yamashita D., Bendele A.M., Maul D., et al. Protective effects of a cathepsin K inhibitor, SB-553484, in the canine partial medial meniscectomy model of osteoarthritis. Osteoarthritis Cartilage 2009, 17:1236-1243.
53. Marks R. Comorbid depression and anxiety impact hip osteoarthritis disability. Disabil Health J 2009, 2:27-35.
54. Conaghan P.G., Vanharanta H., Dieppe P.A. Is progressive osteoarthritis an atheromatous vascular disease?. Ann Rheum Dis 2005, 64:1539-1541.
55. Weinberger M., Tierney W.M., Booher P. Common problems experienced by adults with osteoarthritis. Arthritis Care Res 1989, 2:94-100.
56. Arnoldi C.C., Lemperg R., Linderholm H. Immediate effect of osteotomy on the intramedullary pressure in the femoral head and neck in patients with degenerative osteoarthritis. Acta Orthop Scand 1971, 42:454-455.
57. Arnoldi C.C., Linderholm H., Mussbichler H. Venous engorgement and intraosseous hypertension in osteoarthritis of the hip. JBone Joint Surg Br 1972, 54:409-421.
58. Pedersen N.W., Kiaer T., Kristensen K.D., Starklint H. Intraosseous pressure, oxygenation, and histology in arthrosis and osteonecrosis of the hip. Acta Orthop Scand 1989, 60:415-417.
59. Hunter D.J., Gerstenfeld L., Bishop G., Davis A.D., Mason Z.D., Einhorn T.A., et al. Bone marrow lesions from osteoarthritis knees are characterized by sclerotic bone that is less well mineralized. Arthritis Res Ther 2009, 11:R11.
60. Kim H.A., Cho M.L., Choi H.Y., Yoon C.S., Jhun J.Y., Oh H.J., et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006, 54:2152-2163.
61. Jones S.W., Brockbank S.M., Clements K.M., Le G.N., Campbell D., Read S.J., et al. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) modulates key biological pathways associated with OA disease pathology. Osteoarthritis Cartilage 2009, 17:124-131.
62. Cohen S.B., Proudman S., Kivitz A.J., Burch F.X., Donohue J.P., Burstein D., et al. Arandomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011, 13:R125.
63. Kulkarni S.K., Singh V.P. Licofelone-a novel analgesic and anti-inflammatory agent. Curr Top Med Chem 2007, 7:251-263.
64. Pelletier J.P., Boileau C., Brunet J., Boily M., Lajeunesse D., Reboul P., et al. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 2004, 34:527-538.
65. Raynauld J.P., Martel-Pelletier J., Bias P., Laufer S., Haraoui B., Choquette D., et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 2009, 68:938-947.
66. Bentz M., Zaouter C., Shi Q., Fahmi H., Moldovan F., Fernandes J.C., et al. Inhibition of inducible nitric oxide synthase prevents lipid peroxidation in osteoarthritic chondrocytes. JCell Biochem 2012, 113:2256-2267.
67. Palmer R.M., Hickery M.S., Charles I.G., Moncada S., Bayliss M.T. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 1993, 193:398-405.
68. Hashimoto S., Takahashi K., Amiel D., Coutts R.D., Lotz M. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis Rheum 1998, 41:1266-1274.
69. Scher J., Pillinger M., Abramson S. Nitric oxide synthases and osteoarthritis. Curr Rheumatol Rep 2007, 9:9-15.
70. Jarvinen K., Vuolteenaho K., Nieminen R., Moilanen T., Knowles R.G., Moilanen E. Selective iNOS inhibitor 1400W enhances anti-catabolic IL-10 and reduces destructive MMP-10 in OA cartilage. Survey of the effects of 1400W on inflammatory mediators produced by OA cartilage as detected by protein antibody array. Clin Exp Rheumatol 2008, 26:275-282.
71. More A.S., Kumari R.R., Gupta G., Lingaraju M.C., Balaganur V., Pathak N.N., et al. Effect of iNOS inhibitor S-methylisothiourea in monosodium iodoacetate-induced osteoathritic pain: implication for osteoarthritis therapy. Pharmacol Biochem Behav 2013, 103:764-772.
72. Pelletier J.P., Jovanovic D., Fernandes J.C., Manning P., Connor J.R., Currie M.G., et al. Reduced progression of experimental osteoarthritis invivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum 1998, 41:1275-1286.
73. Pelletier J.P., Jovanovic D., Fernandes J.C., Manning P., Connor J.R., Currie M.G., et al. Reduction in the structural changes of experimental osteoarthritis by a nitric oxide inhibitor. Osteoarthritis Cartilage 1999, 7:416-418.
74. Hellio le Graverand M.P., Clemmer R.S., Redifer P., Brunell R.M., Hayes C.W., Brandt K.D., et al. A2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis 2013, 72:187-195.
75. Hui W., Litherland G.J., Jefferson M., Barter M.J., Elias M.S., Cawston T.E., et al. Lithium protects cartilage from cytokine-mediated degradation by reducing collagen-degrading MMP production via inhibition of the P38 mitogen-activated protein kinase pathway. Rheumatology 2010, 49(11):2043-2053.
76. Brown K., Heitmeyer S., Hookfin E., Hsieh L., Buchalova M., Taiwo Y., et al. P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. JInflamm 2008, 5:1-8.
77. Slemenda C., Heilman D., Brandt K., Katz B., Mazzuca S., Braunstein E., et al. Reduced quadriceps strength relative to body weight - a risk factor for knee osteoarthritis in women?. Arthritis Rheum 1998, 41:1951-1959.
78. Hall M.C., Mockett S.P., Doherty M. Relative impact of radiographic osteoarthritis and pain on quadriceps strength, proprioception, static postural sway and lower limb function. Ann Rheum Dis 2006, 65:865-870.
79. Omori G., Koga Y., Tanaka M., Nawata A., Watanabe H., Narumi K., et al. Quadriceps muscle strength and its relationship to radiographic knee osteoarthritis in Japanese elderly. JOrthop Sci 2013, 18:536-542.
80. Hurley M. The role of muscle weakness in the pathogenesis of osteoarthritis. Rheum Dis Clin North Am 1999, 25:283.
81. Ikeda S., Tsumura H., Torisu T. Age-related quadriceps-dominant muscle atrophy and incident radiographic knee osteoarthritis. JOrthop Sci 2005, 10:121-126.
82. Fink B., Egl M., Singer J., Fuerst M., Bubenheim M., Neuen-Jacob E. Morphologic changes. in the vastus medialis muscle in patients with osteoarthritis of the knee. Arthritis Rheum 2007, 56:3626-3633.
83. Sirca A., Susec-Michieli M. Selective type II fibre muscular atrophy in patients with osteoarthritis of the hip. JNeurol Sci 1980, 44:149-159.
84. Thorstensson C., Petersson I., Jacobsson L., Boegard T., Roos E. Reduced functional performance in the lower extremity predicted radiographic knee osteoarthritis five years later. Ann Rheum Dis 2004, 63:402-407.
85. Segal N.A., Torner J.C., Felson D., Niu J., Sharma L., Lewis C.E., et al. Effect of thigh strength on incident radiographic and symptomatic knee osteoarthritis in a longitudinal cohort. Arthritis Care Res 2009, 61:1210-1217.
86. Baker K., McAlindon T. Exercise for knee osteoarthritis. Curr Opin Rheumatol 2000, 12:456-463.
87. Eyigor S. Acomparison of muscle training methods in patients with knee osteoarthritis. Clin Rheumatol 2004, 23:109-115.
88. Keefe F., Blumenthal J., Baucom D., Affleck G., Waugh R., Caldwell D., et al. Effects of spouse-assisted coping skills training and exercise training in patients with osteoarthritic knee pain: a randomized controlled study. Pain 2004, 110:539-549.
89. Jan M., Lin J., Liau J., Lin Y., Lin D. Investigation of clinical effects of high- and low-resistance training for patients with knee osteoarthritis: a randomized control-led trial. Phys Ther 2008, 88:427-436.
90. Rosemffet M., Schneeberger E., Citera G., Sgobba M., Laiz C., Schmulevich H., et al. Effects of functional electrostimulation on pain, muscular strength, and functional capacity in patients with osteoarthritis of the knee. JCR-J Clin Rheumatol 2004, 10:246-249.
91. Wang Y., Wluka A.E., Berry P.A., Siew T., Teichtahl A.J., Urquhart D.M., et al. Increase in vastus medialis cross-sectional area is associated with reduced pain, cartilage loss, and joint replacement risk in knee osteoarthritis. Arthritis Rheum 2012, 64:3917-3925.
92. Messier S.P., Mihalko S.L., Legault C., Miller G.D., Nicklas B.J., DeVita P., et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA 2013, 310:1263-1273.
93. Sinha-Hikim I., Cornford M., Gaytan H., Lee M.L., Bhasin S. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men. JClin Endocrinol Metab 2006, 91:3024-3033.
94. Zhang J., He Q., Liu Q., Guo W., Deng X., Zhang W., et al. Differential gene expression profile in pig adipose tissue treated with/without clenbuterol. BMC Genomics 2007, 8:433.
95. Zeman R.J., Ludemann R., Easton T.G., Etlinger J.D. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist. Am J Physiol 1988, 254:E726-E732.
96. Larsson L., Li X., Teresi A., Salviati G. Effects of thyroid hormone on fast- and slow-twitch skeletal muscles in young and old rats. JPhysiol 1994, 481(Pt 1):149-161.
97. Tonge D.P., Jones S.W., Parr T., Bardsley R., Doherty M., Maciewicz R.A. β2-Adrenergic agonist-induced hypertrophy of the quadriceps skeletal muscle does not modulate disease severity in the rodent meniscectomy model of osteoarthritis. Osteoarthritis Cartilage 2009, 18:555-562.
98. Wang Y., Simpson J.A., Wluka A.E., Teichtahl A.J., English D.R., Giles G.G., et al. Relationship between body adiposity measures and risk of primary knee and hip replacement for osteoarthritis: a prospective cohort study. Arthritis Res Ther 2009, 11:R31.
99. Cicuttini F.M., Baker J.R., Spector T.D. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. JRheumatol 1996, 23:1221-1226.
100. Oliveria S.A., Felson D.T., Cirillo P.A., Reed J.I., Walker A.M. Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology 1999, 10:161-166.
101. Yang W.S., Chuang L.M. Human genetics of adiponectin in the metabolic syndrome. JMol Med (Berl) 2006, 84:112-121.
102. Lu J.Y., Huang K.C., Chang L.C., Huang Y.S., Chi Y.C., Su T.C., et al. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. JBiomed Sci 2008, 15:565-576.
103. Dyck D.J., Heigenhauser G.J., Bruce C.R. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity. Acta Physiol (Oxf) 2006, 186:5-16.
104. Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM 2005, 98:467-484.
105. Dumond H., Presle N., Terlain B., Mainard D., Loeuille D., Netter P., et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003, 48:3118-3129.
106. Presle N., Pottie P., Dumond H., Guillaume C., Lapicque F., Pallu S., et al. Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 2006, 14:690-695.
107. de Boer T.N., Van Spil W.E., Huisman A.M., Polak A.A., Bijlsma J.W., Lafeber F.P., et al. Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage. Osteoarthritis Cartilage 2012, 20:846-853.
108. Otero M., Lago R., Gomez R., Lago F., Gomez-Reino J.J., Gualillo O. Leptin: a metabolic hormone that functions like a proinflammatory adipokine. Drug News Perspect 2006, 19:21-26.
109. Mutabaruka M.S., Aoulad A.M., Delalandre A., Lavigne M., Lajeunesse D. Local leptin production in osteoarthritis subchondral osteoblasts may be responsible for their abnormal phenotypic expression. Arthritis Res Ther 2010, 12:R20.
110. Chen T.H., Chen L., Hsieh M.S., Chang C.P., Chou D.T., Tsai S.H. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta 2006, 1762:711-718.
111. Lago R., Gomez R., Otero M., Lago F., Gallego R., Dieguez C., et al. Anew player in cartilage homeostasis: adiponectin induces nitric oxide synthase type II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage 2008, 16:1101-1109.
112. Tong K.M., Chen C.P., Huang K.C., Shieh D.C., Cheng H.C., Tzeng C.Y., et al. Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. JCell Biochem 2011, 112:1431-1440.
113. Pasco J.A., Henry M.J., Kotowicz M.A., Collier G.R., Ball M.J., Ugoni A.M., et al. Serum leptin levels are associated with bone mass in nonobese women. JClin Endocrinol Metab 2001, 86:1884-1887.
114. Thomas T., Burguera B., Melton L.J., Atkinson E.J., O'Fallon W.M., Riggs B.L., et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 2001, 29:114-120.
115. Yamauchi M., Sugimoto T., Yamaguchi T., Nakaoka D., Kanzawa M., Yano S., et al. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) 2001, 55:341-347.
116. Berry P.A., Jones S.W., Cicuttini F.M., Wluka A.E., Maciewicz R.A. Temporal relationship between serum adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a population with clinical knee osteoarthritis. Arthritis Rheum 2011, 63:700-707.
117. Honsawek S., Chayanupatkul M. Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch Med Res 2010, 41:593-598.
118. Holliday K.L., McWilliams D.F., Maciewicz R.A., Muir K.R., Zhang W., Doherty M. Lifetime body mass index, other anthropometric measures of obesity and risk of knee or hip osteoarthritis in the GOAL case-control study. Osteoarthritis Cartilage 2011, 19:37-43.
119. Fazeli M., Zarkesh-Esfahani H., Wu Z., Maamra M., Bidlingmaier M., Pockley A.G., et al. Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation. JImmunol Methods 2006, 312:190-200.
120. Matarese G., De Rosa V. Ob-stopping obesity, metabolic and immune-mediated disorders. Structure 2012, 20:385-387.
121. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. NEngl J Med 2000, 343:1594-1602.
122. Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Kouroumalis E.A. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2007, 19:789-794.
123. Guler-Yuksel M., Allaart C.F., Watt I., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., van Schaardenburg D., et al. Treatment with TNF-alpha inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis Cartilage 2010, 18:1256-1262.
124. Li Z., Woo J.M., Chung S.W., Kwon M.Y., Choi J.S., Oh H.J., et al. Therapeutic effect of topical adiponectin in a mouse model of desiccating stress-induced dry eye. Invest Ophthalmol Vis Sci 2013, 54:155-162.
125. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
126. Driban J.B., Sitler M.R., Barbe M.F., Balasubramanian E. Is osteoarthritis a heterogeneous disease that can be stratified into subsets?. Clin Rheumatol 2010, 29:123-131.
127. Duffy M.J., Crown J. Companion biomarkers: paving the pathway to personalized treatment for cancer. Clin Chem 2013, 59:1447-1456.
128. Deyati A., Younesi E., Hofmann-Apitius M., Novac N. Challenges and opportunities for oncology biomarker discovery. Drug Discov Today 2013, 18:614-624.
129. Song R.H., Tortorella M.D., Malfait A.M., Alston J.T., Yang Z., Arner E.C., et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007, 56:575-585.
130. De Savi C., Pape A., Sawyer Y., Milne D., Davies C., Cumming J.G., et al. Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. Bioorg Med Chem Lett 2011, 21:3301-3306.
131. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts invitro and invivo. JBone Miner Res 1995, 10:1478-1487.
132. Moreau M., Rialland P., Pelletier J.-P., Martel-Pelletier J., Lajeunesse D., Boileau C., et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther 2011, 13:R98.
133. Lucht U. Effects of calcitonin on osteoclasts invivo. An ultrastructural and histochemical study. ZZellforsch Mikrosk Anat 1973, 145:75-87.
134. Mastbergen S.C., Lafeber F.P., Bijlsma J.W. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 2002, 41:801-808.
135. Ou Y., Tan C., An H., Jiang D., Quan Z., Tang K., et al. Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. Med Sci Monit 2012, 18:BR247-252.
136. Vuolteenaho K., Moilanen T., Hamalainen M., Moilanen E. Effects of TNFalpha-antagonists on nitric oxide production in human cartilage. Osteoarthritis Cartilage 2002, 10:327-332.
137. Joosten L.A., Helsen M.M., van de Loo F.A., van den Berg W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra. Arthritis Rheum 2008, 58:S110-S122.
138. Zhang Q., Lv H., Chen A., Liu F., Wu X. Efficacy of infliximab in a rabbit model of osteoarthritis. Connect Tissue Res 2012, 53:355-358.
139. Santangelo K.S., Nuovo G.J., Bertone A.L. Invivo reduction or blockade of interleukin-1beta in primary osteoarthritis influences expression of mediators implicated in pathogenesis. Osteoarthritis Cartilage 2012, 20:1610-1618.
140. Rudolphi K., Gerwin N., Verzijl N., van der Kraan P., van den Berg W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003, 11:738-746.
141. Smith R.J., Chin J.E., Sam L.M., Justen J.M. Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness. Arthritis Rheum 1991, 34:78-83.
142. Pelletier J.P., Caron J.P., Evans C., Robbins P.D., Georgescu H.I., Jovanovic D., et al. Invivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012-1019.
143. Pelletier J.P., Fernandes J.C., Jovanovic D.V., Reboul P., Martel-Pelletier J. Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase. JRheumatol 2001, 28:2509-2519.